Silver Book Fact

Anti-VEGF Letter Improvement

Fact image

An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.

Brown D, Nguyen Q, Marcus D, Boyer D, et al. Long-Term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmol. 2013. http://www.aaojournal.org/article/S0161-6420(13)00212-1/abstract. Accessed May 17, 2016

Reference

Title
Long-Term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-month results from two phase III trials: RISE and RIDE
Publication
Ophthalmol
Publication Date
2013
Authors
Brown D, Nguyen Q, Marcus D, Boyer D, et al.
Volume & Issue
Volume 120, Issue 10
Pages
324-30
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • In general, for every 10 mmHg reduction in systolic blood pressure, the risk for any complication related to diabetes is reduced by 12%.  
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • In a trial with 160 participants who had type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification benefited patients with respect to vascular complications and on rates…  
  • To date, multiple genomewide comparisons of thousands of subjects with type 2 diabetes and controls without the disease have identified approximately twenty-five DNA variants that are significantly associated with type…  
  • A statin initiation intervention aimed at Medicare Part D prescription drug plan subscribers with diabetes or coronary artery disease was successful in increasing statin use among this group of members…